- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback